[Federal Register Volume 85, Number 81 (Monday, April 27, 2020)]
[Notices]
[Pages 23365-23366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08879]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-0892]


Prospective Grant of an Exclusive Patent License: Development, 
Production, and Commercialization of a Seasonal Influenza Vaccine

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The U.S. Food and Drug Administration (FDA) is contemplating 
the grant of an Exclusive Patent License to practice the inventions 
embodied in the Patents and Patent Applications listed in the 
SUPPLEMENTARY INFORMATION section of this notice to Sciogen Inc. 
located in San Jose, California.

DATES: Only written comments and/or complete applications for a license 
which are received by the FDA Technology Transfer Program within 15 
days from the date of publication of this notice in the Federal 
Register will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
including inquiries concerning license applications, and comments and 
objections relating to the contemplated Exclusive Patent License should 
be directed to William Ronnenberg, Lead Patent Advisor, Technology 
Transfer Program, Food and Drug Administration, 10903 New Hampshire 
Ave., Silver Spring, MD 20993; [email protected].

FOR FURTHER INFORMATION CONTACT: William Ronnenberg, Lead Patent 
Advisor, Technology Transfer Program, Food and Drug Administration, 
10903 New Hampshire Ave., Silver Spring, MD 20993; 240-402-4561, 
[email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    1. U.S. Patent No. 9,163,068 issued October 20, 2015, entitled, 
``Influenza Virus Recombinant Proteins'' (FDA Ref. No. E-2010-004/US-
03).
    2. U.S. Patent No. 9,896,484 issued February 20, 2018, entitled, 
``Influenza Virus Recombinant Proteins'' (FDA Ref. No. E-2010-004/US-
04).
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States.
    The prospective exclusive license territory may be limited to the 
United States for certain of the rights, or

[[Page 23366]]

worldwide, and the field of use may be limited to the following:
    ``The development, production, and commercialization of seasonal 
influenza vaccines.''
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless, within 15 
days from the date of this published notice, the Technology Transfer 
Program at FDA receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this notice, the public may file comments or 
objections (See, ADDRESSES). Comments and objections, other than those 
in the form of a completed license application, will not be treated 
confidentially, and may be made publicly available.
    License applications submitted in response to this notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 21, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-08879 Filed 4-24-20; 8:45 am]
 BILLING CODE 4164-01-P